Kalydeco was just named "The Most Important New Drug of 2012" by Forbes Magazine (here), for three main reasons:
- It is a genomics breakthrough, directly countering a genetic defect
- It was driven, in large part, by the Cystic Fibrosis Foundation, who is absolutely leading patient advocacy groups by example.
- It makes money for both the company who invented in it AND the CFF, who was visionary (and brave) enough to make the investment years ago. The royalties from this drug will help fund future treatments-- this is innovation, and dare we say, capitalism, at its best.